Abbott Laboratories (ABT) is back in focus after fresh momentum in its Medical Devices unit, where electrophysiology products and new launches coincide with expanded rapid testing offerings and fresh partnerships in point-of-care diagnostics.
Recent news on Abbott Laboratories’ electrophysiology launches and new rapid tests comes against a mixed share price backdrop, with a 1-day share price return of 1.18% and a year-to-date share price decline of 12.62%. The 3-year total shareholder return is up 14.22%, but the 1-year total shareholder return is down 14.47%, suggesting short-term pressure even as longer-term holders still sit on gains, with momentum fading rather than accelerating.
Scan Abbott Laboratories’ peers for other device and diagnostics players showing fresh momentum by running the hand-picked 30 resilient stocks with low risk scores alongside this update.
For Abbott Laboratories, the bullish story leans on medical devices and rapid testing progress, while the bearish side points to recent share price pressure. Which case looks more convincing when compared with the current valuation?
According to the analyst consensus Narrative on Simply Wall St, Abbott Laboratories screens as undervalued, with a fair value of $120.26 compared to a last close of $108.52. This suggests the current price reflects a discount despite recent medical device momentum.
The main factor that needs to hold is that Abbott Laboratories continues to convert its medical technology pipeline in areas such as continuous glucose monitoring, electrophysiology and cancer diagnostics into sustained sales growth and margin expansion, while managing Nutrition legal and regulatory risks.
See why 195 investors see Abbott Laboratories as 10% undervalued.
Result: Fair Value of $120.26 (UNDERVALUED)
Still, Abbott Laboratories faces real swing factors, including further Nutrition legal costs and any potential reset in market appetite for a higher P/E multiple.
Find out about the key risks to this Abbott Laboratories narrative.
The analyst narrative leans on a fair value of $120.26, yet Abbott Laboratories currently trades on a P/E of 40.2x. That is higher than both the US Medical Equipment industry at 25.3x and peers at 37.6x, and only fractionally above a 40.1x fair ratio. This points to limited room if sentiment cools, and raises the question: how much multiple risk are you comfortable holding for a stock already priced at the top of its group?
For a closer look at how that earnings multiple compares across peers and sectors, See what the numbers say about this price — find out in our valuation breakdown..
Mixed messages on Abbott Laboratories so far. Use that tension as a prompt to move fast, review the underlying data, and weigh both the bull and bear cases against your own objectives by checking the 2 key rewards and 3 important warning signs.
Do not stop with Abbott Laboratories alone. Broaden your watchlist with a few focused screens that surface very different types of opportunities other investors might overlook.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com